Incidence, treatment, and outcomes of atrial fibrillation complicating non-ST-segment elevation acute coronary syndromes.

[1]  Giuseppe Ambrosio,et al.  Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. , 2012, The New England journal of medicine.

[2]  Paul Burton,et al.  Rivaroxaban in patients with a recent acute coronary syndrome. , 2012, The New England journal of medicine.

[3]  R. Mehta,et al.  Naproxen as prophylaxis against atrial fibrillation after cardiac surgery: the NAFARM randomized trial. , 2011, The American journal of medicine.

[4]  J. Lessick,et al.  Transient atrial fibrillation and risk of stroke after acute myocardial infarction , 2011, Thrombosis and Haemostasis.

[5]  Deepak L. Bhatt,et al.  Apixaban with antiplatelet therapy after acute coronary syndrome. , 2011, The New England journal of medicine.

[6]  X. Jouven,et al.  Atrial Fibrillation and Death After Myocardial Infarction: A Community Study , 2011, Circulation.

[7]  Hani Jneid,et al.  2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in c , 2011, Journal of the American College of Cardiology.

[8]  X. Jouven,et al.  Mortality Associated With Atrial Fibrillation in Patients With Myocardial Infarction: A Systematic Review and Meta-Analysis , 2011, Circulation.

[9]  Silvia G Priori,et al.  2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2011, Circulation.

[10]  Kenneth A Ellenbogen,et al.  2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2011, Circulation.

[11]  Fredrik Folke,et al.  Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. , 2010, Archives of internal medicine.

[12]  L. Newby,et al.  Warfarin use and outcomes in patients with atrial fibrillation complicating acute coronary syndromes. , 2010, The American journal of medicine.

[13]  Gregory Y H Lip,et al.  Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. , 2010, Chest.

[14]  L. Køber,et al.  Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data , 2009, The Lancet.

[15]  R. Califf,et al.  Early versus delayed, provisional eptifibatide in acute coronary syndromes. , 2009, The New England journal of medicine.

[16]  P. Sanders,et al.  Prognostic impact of types of atrial fibrillation in acute coronary syndromes. , 2009, The American journal of cardiology.

[17]  R. Califf,et al.  Patterns of management of atrial fibrillation complicating coronary artery bypass grafting: Results from the PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT-IV) Trial. , 2009, American heart journal.

[18]  Claes Held,et al.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.

[19]  P. Armstrong,et al.  Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary intervention: results from the APEX-AMI trial. , 2009, European heart journal.

[20]  L. Newby,et al.  Short- and long-term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST-segment elevation , 2008, Heart.

[21]  E. Antman,et al.  Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.

[22]  C. Lau,et al.  Transient atrial fibrillation complicating acute inferior myocardial infarction: implications for future risk of ischemic stroke. , 2007, Chest.

[23]  I. Porto,et al.  Adjusted indirect meta-analysis of aspirin plus warfarin at international normalized ratios 2 to 3 versus aspirin plus clopidogrel after acute coronary syndromes. , 2007, The American journal of cardiology.

[24]  J. Hartikainen,et al.  Corticosteroids for the prevention of atrial fibrillation after cardiac surgery: a randomized controlled trial. , 2007, JAMA.

[25]  Ajai Kumar Jain,et al.  PexeLizumab for Acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: A randomized controlled trial , 2007 .

[26]  A. Keech,et al.  Interventions for prevention of post-operative atrial fibrillation and its complications after cardiac surgery: a meta-analysis. , 2006, European heart journal.

[27]  V. Pasceri,et al.  Randomized Trial of Atorvastatin for Reduction of Postoperative Atrial Fibrillation in Patients Undergoing Cardiac Surgery: Results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) Study , 2006, Circulation.

[28]  G. Lip,et al.  Is atrial fibrillation an inflammatory disorder? , 2006, European heart journal.

[29]  J. Cook,et al.  Warfarin plus Aspirin after Myocardial Infarction or the Acute Coronary Syndrome: Meta-Analysis with Estimates of Risk and Benefit , 2005, Annals of Internal Medicine.

[30]  S. Yusuf,et al.  Clinical ResearchHeart Rhythm DisorderPrevention of Atrial Fibrillation With Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: A Meta-Analysis , 2005 .

[31]  R. Califf,et al.  The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndro , 2005, American heart journal.

[32]  K. Eagle,et al.  Comparison of outcomes of patients with acute coronary syndromes with and without atrial fibrillation. , 2003, The American journal of cardiology.

[33]  Á. Avezum,et al.  Predictors of hospital mortality in the global registry of acute coronary events. , 2003, Archives of internal medicine.

[34]  L. Hadjinikolaou,et al.  Incidence and Clinical Consequences of Atrial Fibrillation Within 1 Year of First-Time Isolated Coronary Bypass Surgery , 2003, Circulation.

[35]  R. Califf,et al.  Management and outcome of patients with atrial fibrillation during acute myocardial infarction: the GUSTO-III experience , 2002 .

[36]  S. Yusuf,et al.  Interventions on Prevention of Postoperative Atrial Fibrillation in Patients Undergoing Heart Surgery: A Meta-Analysis , 2002, Circulation.

[37]  W. Stevenson,et al.  Atrial Fibrillation after Cardiac Surgery , 2001, Annals of Internal Medicine.

[38]  S. Yusuf,et al.  Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. , 2001, The New England journal of medicine.

[39]  Martha J. Radford,et al.  Validation of Clinical Classification Schemes for Predicting Stroke: Results From the National Registry of Atrial Fibrillation , 2001 .

[40]  R. Beyth,et al.  Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. , 1998, The American journal of medicine.

[41]  V. Boyko,et al.  Significance of Paroxysmal Atrial Fibrillation Complicating Acute Myocardial Infarction in the Thrombolytic Era , 1998 .

[42]  G. W. Snedecor.  STATISTICAL METHODS , 1967 .